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Abstract In this study, we report that Src kinase is inhibited by
protein phosphatase 2A (PP2A), a serine/threonine phosphatase.
We carried out experiments in vitro using purified PP2A (AC
dimer) and full-length v-Src or truncated forms of v-Src. The
inhibition of v-Src by PP2A is concentration- and time-
dependent. Addition of okadaic acid, a PP2A phosphatase
inhibitor, abolished the PP2A-dependent inhibition of v-Src.
When experiments were carried out at 4‡C under conditions
where PP2A activity is inhibited, Src activity was unaffected by
the presence of PP2A, suggesting that PP2A binding alone is
insufficient to block Src activity. These results imply that PP2A
activity is essential for inhibition of v-Src. We also demonstrate
that PP2A binds to the catalytic and the regulatory domains of
v-Src. ß 2001 Published by Elsevier Science B.V. on behalf of
the Federation of European Biochemical Societies.
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1. Introduction
Members of the Src kinase family have important roles in
controlling growth, proliferation, and di¡erentiation [1,2]. Src
kinases are composed of an N-terminal membrane binding
region, a unique domain, an SH3 domain that binds pro-
line-rich sequences, a phosphotyrosine binding SH2 domain,
a tyrosine kinase catalytic domain, and a C-terminal tail [2,3].
Src family kinase activity is negatively regulated by intramo-
lecular interactions involving the SH3 and SH2 domains [4,5].
Src kinase activity is also regulated positively or negatively by
tyrosine phosphorylation in the kinase activation loop and
C-terminal tail, respectively [4,5].
Protein phosphatase 2A (PP2A) is a widely expressed ser-
ine/threonine phosphatase involved in the regulation of signal
transduction, growth and development [6^8]. The PP2A holo-
enzyme is composed of catalytic (C), structural (A) and reg-
ulatory (B) subunits [7^9]. The core heterodimer (AC) forms
complexes with various regulatory subunits, giving rise to dif-
ferent substrate speci¢cities and intracellular localizations.
PP2A is also regulated by posttranslational modi¢cations to
the C subunit such as phosphorylation [10^12] and carboxy-
methylation [13,14].
Various serine/threonine protein kinases are known to form
stable complexes with PP2A and to be regulated by PP2A
[6,7]. However, relatively few tyrosine kinases have been re-
ported to associate with PP2A. Tyrosine phosphorylation of
PP2A occurs in response to growth factor stimulation and
v-Src transformation of ¢broblasts. Src, p56lck, the epidermal
growth factor (EGF) receptor, and insulin receptor can phos-
phorylate the carboxy-terminal region of the C subunit of
PP2A (Tyr-307), resulting in inhibition of phosphatase activ-
ity [10,11]. Replacement of this tyrosine with an acidic residue
abolishes the interaction between the AC heterodimer and the
B subunit [15]. Recently, we have reported that Jak2, a mem-
ber of a di¡erent family of tyrosine kinases, also phosphor-
ylates the C subunit of PP2A and inhibits PP2A [16]. Thus,
tyrosine phosphorylation of the C subunit is one of the regu-
latory mechanisms of PP2A.
Src kinase has been reported to form a complex with PP2A
[17^21]. PP2A has also been found to associate with SV40
small T-antigen and polyoma virus middle T-antigen (MT),
resulting in changes in PP2A activity or substrate speci¢city
[22^24]. Both small T-antigen and MT form complexes with
the 65-kDa putative regulatory subunit (PR65)/C subunit
dimer of PP2A [17,25]. MT induces cell transformation by
associating with and modulating the activities of cellular pro-
teins involved in cell proliferation. MT binds three members
of the Src family kinase, pp60cÿsrc [26], pp62cÿyes [27] and
pp59cÿfyn [28,29]. MT/Src complexes contain equimolar
amounts of PP2A [20]. However, it is not clear whether Src
associates directly with PP2A. The physiological functions of
Src^PP2A complexes have not been completely elucidated. In
particular, the e¡ect of complex formation on Src kinase ac-
tivity has not been investigated. In this study, we analyzed the
e¡ect of the PP2A^Src association using puri¢ed protein com-
ponents. We show that the interaction is direct, that PP2A
binding decreases Src tyrosine kinase activity, and that PP2A
binds to SH2 and SH3 domains in addition to the catalytic
domain of Src.
2. Materials and methods
2.1. Materials
PP2A protein (heterodimer of C subunit and A subunit), PP2A
C subunit antibody and phosphotyrosine antibody (4G10) were ob-
tained from Upstate Biotechnology (Lake Placid, NY, USA). Okadaic
acid (OA) and protein A-agarose were from Sigma. [Q-32P]ATP was
from Amersham Pharmacia Biotech (Piscataway, NJ, USA). Ni-NTA
resin was from Qiagen. E4IYM4 (KKEEEEIYMMMM) peptide was
synthesized on an Applied Biosystems automated peptide synthesizer
and puri¢ed by reverse-phase high performance liquid chromatogra-
phy. Glutathione-agarose and glutathione S-transferase (GST) anti-
body were from Molecular Probes (Eugene, OR, USA). The (HA)3-
tagged PP2A C subunit expression plasmid was a gift from Dr. David
Brautigan (University of Virginia, Charlottesville, VA, USA). The
Ts-72 cell line (NIH 3T3 ¢broblasts transformed by a temperature-
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sensitive mutant of Src) was obtained from Dr. Steven M. Anderson
(University of Colorado Health Science Center, Denver, CO, USA).
Ts-72 cells were cultured in Dulbecco’s modi¢ed Eagle’s medium sup-
plemented with 10% of fetal bovine serum and antibiotics at 39‡C.
For activation of Src, cells were cultured at 34‡C for 2 days.
2.2. Expression and puri¢cation of v-Src
Expression of the full-length 60-kDa Rous sarcoma virus v-Src gene
product was carried out in Spodoptera frugiperda (Sf9) cells infected
with a recombinant baculovirus harboring the v-Src gene [30]. Immu-
noa⁄nity puri¢cation of v-Src was performed as described previously
[30].
To produce the truncated form of v-Src lacking the unique region,
v-Src DNA from the Schmidt-Ruppin strain of Rous sarcoma virus
(encoding amino acids 77^526, comprising the SH3, SH2 and catalytic
domain of v-Src) was subcloned into pFastBacHTb (Gibco BRL) as a
BamHI/EcoRI fragment. Truncated v-Src was expressed in Sf9 cells
and puri¢ed using Ni-NTA resin, followed by a hydroxyapatite col-
umn, as described previously [31].
The following domains of v-Src were expressed in Escherichia coli
as GST fusion proteins: SH2, SH3^SH2, catalytic, and SH2^catalytic.
The SH2 domains of Nck and SHP2 were also expressed in E. coli as
GST fusion proteins. Expression of the GST fusion proteins was
carried out in bacterial strain NB42, and the constructs were puri¢ed
on glutathione-agarose as described previously [32].
2.3. Src kinase assay
Src activity was measured using the phosphocellulose binding assay.
Assays were carried out in 20 Wl at either or 30‡C or 4‡C, as described
previously [31]. The reaction mixtures contained 20 mM Tris^HCl
(pH 7.4), 10 mM MgCl2, 0.1 mM Na3VO4, 5 mg/ml bovine serum
albumin (BSA), 0.25 mM ATP, 0.5 mM E4IYM4 peptide
(KKEEEEIYMMMM) and [Q-32P]ATP (200^300 cpm/pmol) with or
without PP2A (heterodimer of C subunit and A subunit, Upstate
Biotechnology). Reactions were terminated by addition of 50% acetic
acid and spotted on P81 paper. After washing with 0.5% phosphoric
acid, incorporation of 32P into peptides was determined by liquid
scintillation counting.
2.4. Pull-down experiments using GST fusion proteins
Ts-72 cells were harvested, washed twice with ice-cold phosphate-
bu¡ered saline, and lysed in lysis bu¡er (10 mM Tris^HCl (pH 7.5),
5 mM EDTA, 50 mM NaF, 2 mM Na3VO4, 10 mM dithiothreitol,
1% Nonidet P-40 (NP-40), 0.05% SDS, 0.25% sodium deoxycholate,
1 mM phenylmethylsulfonyl £uoride, 10 Wg/ml leupeptin, 10 Wg/ml
aprotinin) at 4‡C for 30 min. Cell lysates were centrifuged at
15 000Ug for 10 min. The resulting supernatants (1 mg cellular pro-
teins) were used for GST-catalytic, GST-SH2^catalytic, GST-SH2 or
GST-SH3^SH2 pull-down experiments. After addition of 10 Wl of
GST fusion proteins coupled to glutathione-agarose (or GST-agarose
gel as a control), incubations were continued 5 h at 4‡C. The resin was
collected and washed four times with phosphate-bu¡ered saline plus
0.5% NP-40. The precipitated proteins were analyzed on a 7.5% SDS^
polyacrylamide gel. For Western blot analysis, proteins in the gel were
transferred to Immobilon membrane (Millipore, Bedford, MA, USA)
in the presence of 0.1% SDS. The membranes were blocked using 5%
milk in Tris-bu¡ered saline plus 0.1% Tween 20, then probed with
GST, phosphotyrosine or PP2A antibodies. Blots were visualized the
horseradish peroxidase-conjugated second antibody with ECL (En-
hanced Chemiluminescence, Amersham). Pull-down experiments
with the GST-SH2 domains of Nck and SHP2 were performed in a
similar manner.
2.5. Pull-down experiments using immobilized PP2A
Immobilized PP2A was prepared as described previously [33].
Brie£y, an expression vector encoding (HA)3-tagged PP2A C subunit
was transfected into COS-7 cells. Cells were harvested after 24 h and
HA antibody was added to the cell lysates. Protein A-agarose was
added and then incubated overnight. For some experiments, the im-
mobilized PP2A C subunit was phosphorylated by addition of v-Src
(0.04 Wg) at 30‡C for 1 h in kinase assay bu¡er. As a control, non-
phosphorylated PP2A C subunit was prepared by addition of v-Src
without ATP in kinase bu¡er. Pull-down reactions were carried out by
incubating Src constructs with immobilized PP2A (or mouse IgG
protein agarose as a control) overnight at 4‡C.
3. Results and discussion
3.1. Inhibition of Src activity by PP2A in vitro
To analyze the e¡ect of PP2A on Src activity, truncated
v-Src was incubated with various concentrations of PP2A
for 30 min. As shown in Fig. 1A, Src activity becomes inhib-
ited with incubation of exogenous PP2A. Maximum inhibition
of Src activity occurred at a ratio of about 0.9 mol of PP2A to
one mol of Src, and inhibition seems to plateau at molar
ratios higher than 1:1 (see below). Similar results were ob-
tained using full-length v-Src (result not shown).
We next analyzed the time course of v-Src inhibition using a
PP2A:Src ratio of 1.2 (Fig. 1B). The time-dependent inhibi-
tion of v-Src reached a plateau after 15 min. One possible
explanation for the plateau is that tyrosine phosphorylation
of PP2A is likely to occur in the reaction mixture. Tyrosine
phosphorylation of the C subunit of PP2A by Src and other
tyrosine kinases has previously been shown to inhibit PP2A
Fig. 1. Inhibition of Src by PP2A. A: The activity of v-Src was
measured after 30 min of incubation with various amounts of
PP2A. Src activity was measured using 0.5 mM E4IYM4 peptide.
The activity of Src in the absence of PP2A was taken as 100%.
B: Src activity was measured after di¡erent times of incubation
with 1.2 mol PP2A per mol Src. The activity of Src alone was taken
as 100%. Closed circles: assays performed at 30‡C; open circles: as-
says performed at 4‡C. Closed square: addition of 2.4 mol of PP2A
at 15 min, followed by an additional 15 min incubation.
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[10,11,16]. Thus, even at higher concentrations of PP2A, the
available PP2A activity for Src inhibition may become lim-
ited. We tested this by adding additional PP2A to a Src^PP2A
reaction mixture after 15 min. This treatment resulted in fur-
ther inhibition of Src (Fig. 1B).
We investigated whether the phosphatase activity of PP2A
is necessary for inhibition of v-Src. (An alternative possibility
is that PP2A binding alone is su⁄cient to inhibit v-Src.) It is
well established that PP2A activity is not required for binding
to Src [20,21,33]. Thus, we carried out experiments under two
conditions in which PP2A activity is inhibited. First, we per-
formed experiments in the presence of OA, a speci¢c PP2A
phosphatase inhibitor. As shown in Table 1, OA abolished the
inhibitory e¡ect of PP2A. These data imply that PP2A activity
is necessary for inhibition of v-Src. We also performed experi-
ments at 4‡C; PP2A is completely inhibited under these con-
ditions, but Src retains signi¢cant activity (results not shown).
Under these assay conditions, PP2A did not show any inhi-
bition of Src activity (Fig. 1B). Thus, using two di¡erent ap-
proaches, we demonstrated that PP2A activity is required to
inhibit Src activity in vitro. We speculate tyrosine-phosphor-
ylated PP2A would be released from the Src^PP2A complex
in vivo, and would subsequently regain its activity by autode-
phosphorylation [10,11].
3.2. Mapping of PP2A binding sites on Src
The binding sites for PP2A on Src have not previously been
determined. The principal sites for serine/threonine phosphor-
ylation of Src lie in the N-terminal unique region [1]. The
unique region contains protein kinase (PK) A (Ser-17) and
PKC (Ser-12, 48) phosphorylation sites, although the role of
serine/threonine phosphorylation is currently not clear [1].
The presence of these phosphorylation sites suggested that
the unique region might be the point of contact with PP2A.
To investigate the importance of the Src unique region in
complex formation with PP2A, a construct consisting of the
SH3, SH2, and catalytic domains of v-Src was incubated with
PP2A in vitro. The reaction was subjected to immunoprecipi-
tation with PP2A antibody and analyzed by Western blotting
with Src antibody. As shown in Fig. 2, the SH3^SH2^catalytic
domain construct was immunoprecipitated by PP2A antibody
as well as full-length v-Src. These data show a direct interac-
tion between the two molecules in vitro, and suggest that the
N-terminal membrane binding and unique domains of Src are
dispensable for binding to PP2A. When puri¢ed from Sf9
cells, the SH3^SH2^catalytic domain construct has no detect-
able serine phosphorylation (as judged by Western blotting
with anti-phosphoserine antibody). Thus, inhibition of Src
activity by PP2A is most likely not related to dephosphoryla-
tion of serine/threonine residues on Src. At present, the mech-
anism of inhibition of Src activity by PP2A is not clear.
To analyze the potential involvement of the Src SH2 do-
main on PP2A binding, we prepared GST fusion proteins
containing the catalytic domain and the SH2^catalytic do-
Fig. 2. Immunoprecipitation of full-length and truncated v-Src by
PP2A in vitro. Puri¢ed PP2A (dimer of A and C subunits, 0.1 Wg)
was incubated with full-length v-Src (0.37 Wg) or histidine-tagged
truncated v-Src (0.37 Wg) in the presence of 500 Wg BSA. Immuno-
precipitation reactions were carried out using PP2A antibody or
mouse IgG as control. Bound proteins were subjected to SDS^
PAGE and analyzed with polyclonal Src antibody or PP2A antibod-
ies. The results are representative of four independent experiments.
Fig. 3. GST pull-down experiments. Immobilized GST fusion proteins were incubated with lysates (1 mg protein) from Ts-72 cells grown at the
permissive and non-permissive temperatures. Bound proteins were separated by SDS^PAGE and analyzed by immunoblotting with PP2A and
phosphotyrosine antibodies. Lane 1: GST; lane 2: GST-Nck SH2; lane 3: GST-SHP2 SH2; lane 4: GST-Src catalytic domain; lane 5: GST-
SH2^catalytic domains of Src. The results are representative of three independent experiments.
Table 1
E¡ect of OA on Src inhibition by PP2A
OA (nM) Src activity (% of control)
0 66.7 þ 9.6
25 79.6 þ 8.3
50 91.2 þ 8.4
100 98.0 þ 7.6
Src activity in the presence of PP2A (1.2-fold molar excess) was de-
termined after 30 min incubation with di¡erent concentrations of
OA in the assay. Src activity without incubation with PP2A was
taken as 100%.
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mains of v-Src. We used these fusion proteins to analyze pro-
teins in Ts-72 cell lysates that speci¢cally bound to the Src
domains. The tsNY72-4 mutant form of v-Src expressed in
these cell lines results in a tumorigenic phenotype only when
cells are cultured at the permissive temperature [34]. Experi-
ments were carried out at both the Src permissive (34‡C) and
Src non-permissive (39‡C) temperatures. We have previously
reported that tyrosine phosphorylation of PP2A was increased
by shifting from the non-permissive to the permissive temper-
ature in Ts-72 cells [33]. Bound proteins were analyzed by
immunoblotting with phosphotyrosine and PP2A antibodies
(Fig. 3). In all experiments, we used similar amounts of GST
fusion proteins (results not shown).
PP2A bound to the catalytic domain of Src, and the bind-
ing of PP2A was stronger when lysates were prepared from
cells grown at the Src permissive temperature (Fig. 3). PP2A
also interacts with the SH2^catalytic construct. In contrast,
tyrosine-phosphorylated PP2A interacted with the SH2^cata-
lytic construct, but not with the catalytic domain alone, as
shown by reblotting with phosphotyrosine antibody (Fig. 3).
The lack of binding between tyrosine-phosphorylated PP2A
and the catalytic domain of Src is consistent with the spec-
ulation that tyrosine-phosphorylated PP2A is released from
the complex with Src. Tyrosine-phosphorylated PP2A also
interacted with a GST fusion protein containing the isolated
SH2 domain of Src (results not shown).
We investigated the speci¢city of PP2A binding to the Src
SH2 domain using SH2 domains from the Nck adapter pro-
tein and from the tyrosine phosphatase SHP2. PP2A inter-
acted with the Nck-SH2, but in this case the bound PP2A
did not react with anti-phosphotyrosine antibody (Fig. 3).
The SH2 domain of SHP2 showed only a weak interaction
with PP2A. These results suggest that tyrosine-phosphorylat-
ed PP2A preferentially binds to the SH2 domain of Src.
We carried out additional experiments to investigate the
binding of tyrosine-phosphorylated PP2A to the Src SH2 do-
main. Immobilized PP2A C subunit (tyrosine-phosphorylated
or unphosphorylated) was incubated with the GST-SH2 do-
main. The Src SH2 domain bound to the phosphorylated
PP2A C subunit, but not to unphosphorylated PP2A (Fig.
4). Tyrosine phosphorylation of the PP2A C subunit was con-
¢rmed by phosphotyrosine immunoblotting. In parallel ex-
periments with a construct containing the SH3^SH2^catalytic
domains of Src, unphosphorylated PP2A bound more
strongly than tyrosine-phosphorylated PP2A (data not
shown). This suggests that an intramolecular interaction be-
tween SH3, SH2 and catalytic domains may limit the access of
tyrosine-phosphorylated PP2A to the SH2 domain.
The PP2A C subunit contains no typical Src SH2 binding
sequence (pY-E/D-E/D-hydrophobic). Tyr-307 at the carboxy-
terminus of the C subunit of PP2A (in the sequence
TRRTPDYFL) is the site reported to be tyrosine-phosphory-
lated by Src, p56lck, epidermal growth factor receptors and
insulin receptors [10,11]. The result in Fig. 4 implies that
Tyr-307 is involved in binding to the SH2 domain of Src.
At present, there are no other reported sites of tyrosine phos-
phorylation on the C subunit. However, we cannot exclude
the possible involvement of another tyrosine phosphorylation
site. The carboxy-terminus of the PP2A C subunit is highly
conserved and has been shown to be methylated in vivo at
Leu-309 [13,15,35]. Methylation could potentially regulate the
association between Src and PP2A. The PP2A C subunit con-
tains a phosphorylation site at Thr-304 in addition to Tyr-307.
The carboxy-terminus is important in speci¢c binding to
B subunits [15], raising the possibility that the phosphoryla-
tion status of the C-terminus may in£uence holoenzyme as-
sembly of PP2A.
Acknowledgements: We thank Dr. Steven M. Anderson for Ts-72 cells
and Dr. David Brautigan for (HA)3-tagged PP2A C subunit plasmid.
This work was supported by National Institutes of Health Grant CA
28146 (to W.T.M.)
References
[1] Brown, M.T. and Cooper, J.A. (1996) Biochim. Biophys. Acta
1287, 121^149.
[2] Cooper, J.A. and Howell, B. (1993) Cell 73, 1051^1054.
[3] Pawson, T. (1995) Nature 373, 573^580.
[4] Xu, W., Harrison, S.C. and Eck, M.J. (1997) Nature 385, 595^
602.
[5] Sicheri, F., Moare¢, I. and Kuriyan, J. (1997) Nature 385, 602^
609.
[6] Hunter, T. (1995) Cell 83, 1^4.
[7] Millward, T.A., Zolnierowicz, S. and Hemmings, B.A. (1999)
Trends Biochem. Sci. 24, 186^191.
[8] Goldberg, Y. (1999) Biochem. Pharmacol. 57, 321^328.
[9] Shenolikar, S. and Nairn, A.C. (1991) Adv. Second Messenger
Phosphoprotein Res. 23, 1^121.
[10] Chen, J., Martin, B.L. and Brautigan, D.L. (1992) Science 257,
1261^1264.
[11] Chen, J., Parsons, S. and Brautigan, D.L. (1994) J. Biol. Chem.
269, 7957^7962.
[12] Guo, H. and Damuni, Z. (1993) Proc. Natl. Acad. Sci. USA 90,
2500^2504.
[13] Favre, B., Zolnierowicz, S., Turowski, P. and Hemmings, B.A.
(1994) J. Biol. Chem. 269, 16311^16317.
[14] Kowluru, A., Seavey, S.E., Rabaglia, M.E., Nesher, R. and
Metz, S.A. (1996) Endocrinology 137, 2315^2323.
[15] Ogris, E., Gibson, D.M. and Pallas, D.C. (1997) Oncogene 15,
911^917.
[16] Yokoyama, N., Reich, N.C. and Miller, W.T. (2001) J. Interfer-
on Cytokine Res. 21, 369^378.
[17] Pallas, D.C., Shahrik, L.K., Martin, B.L., Jaspers, S., Miller,
T.B., Brautigan, D.L. and Roberts, T.M. (1990) Cell 60, 167^176.
[18] Glenn, G.M. and Eckhart, W. (1993) J. Virol. 67, 1945^1952.
[19] Campbell, K.S., Auger, K.R., Hemmings, B.A., Roberts, T.M.
and Pallas, D.C. (1995) J. Virol. 69, 3721^3728.
[20] Glover, H.R., Brewster, C.E. and Dilworth, S.M. (1999) Onco-
gene 18, 4364^4370.
Fig. 4. Pull-down experiments with (HA)3-tagged PP2A C subunit.
Immobilized PP2A (or tyrosine-phosphorylated PP2A, designated
pY-PP2A) was washed twice with PBS containing 0.5% NP-40, then
incubated with a GST fusion protein containing the SH2 domain of
Src (1.5 Wg) at 4‡C overnight. Bound proteins were analyzed by
SDS^PAGE and Western immunoblotting with anti-HA, phospho-
tyrosine and GST antibodies. The results are representative of three
independent experiments.
FEBS 25272 14-9-01
N. Yokoyama, W.T. Miller/FEBS Letters 505 (2001) 460^464 463
[21] Ogris, E., Mudrak, I., Mak, E., Gibson, D. and Pallas, D.C.
(1999) J. Virol. 73, 7390^7398.
[22] Scheidtmann, K.H., Mumby, M.C., Rundell, K. and Walter, G.
(1991) Mol. Cell. Biol. 11, 1996^2003.
[23] Yang, S.I., Lickteig, R.L., Estes, R., Rundell, K., Walter, G. and
Mumby, M.C. (1991) Mol. Cell. Biol. 11, 1988^1995.
[24] Cayla, X., Ballmer-Hofer, K., Merlevede, W. and Goris, J. (1993)
Eur. J. Biochem. 214, 281^286.
[25] Walter, G., Ruediger, R., Slaughter, C. and Mumby, M. (1990)
Proc. Natl. Acad. Sci. USA 87, 2521^2525.
[26] Courtneidge, S.A. and Smith, A.E. (1983) Nature 303, 435^439.
[27] Kornbluth, S., Sudol, M. and Hanafusa, H. (1987) Nature 325,
171^173.
[28] Kypta, R.M., Hemming, A. and Courtneidge, S.A. (1988) EMBO
J. 7, 3837^3844.
[29] Horak, I.D., Kawakami, T., Gregory, F., Robbins, K.C. and
Bolen, J.B. (1989) J. Virol. 63, 2343^2347.
[30] Garcia, P., Shoelson, S.E., George, S.T., Hinds, D.A., Goldberg,
A.R. and Miller, W.T. (1993) J. Biol. Chem. 268, 25146^25151.
[31] Yokoyama, N. and Miller, W.T. (1999) FEBS Lett. 456, 403^408.
[32] Xu, B. and Miller, W.T. (1996) Mol. Cell. Biochem. 158, 57^63.
[33] Yokoyama, N. and Miller, W.T. (2001) Oncogene (in press).
[34] Mayer, B.J., Jove, R., Krane, J.F., Poirier, F., Calothy, G. and
Hanafusa, H. (1986) J. Virol. 60, 858^867.
[35] Bryant, J.C., Westphal, R.S. and Wadzinski, B.E. (1999) Bio-
chem. J. 339, 241^246.
FEBS 25272 14-9-01
N. Yokoyama, W.T. Miller/FEBS Letters 505 (2001) 460^464464
